Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis

Maria Højberg Knudsen*, Ulrich Lindberg, Jette Lautrup Frederiksen, Mark Bitsch Vestergaard, Helle Juhl Simonsen, Aravinthan Varatharaj, Ian Galea, Morten Blinkenberg, Finn Sellebjerg, Henrik Bo Wiberg Larsson, Stig Præstekjær Cramer

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience

Agricultural and Biological Sciences